Drug delivery technologies have enabled the development of many pharmaceutical
products that improve patient health by enhancing the delivery of a therapeutic to its target …

Protein–protein interactions (PPIs) execute many fundamental cellular functions and have
served as prime drug targets over the last two decades. Interfering intracellular PPIs with …

In contrast to the major families of small molecules and antibodies, cyclic peptides, as a
family of synthesizable macromolecules, have distinct biochemical and therapeutic …

Intracellular delivery is a key step in biological research and has enabled decades of
biomedical discoveries. It is also becoming increasingly important in industrial and medical …

Approximately 75% of all disease-relevant human proteins, including those involved in
intracellular protein–protein interactions (PPIs), are undruggable with the current drug …

We use computational design coupled with experimental characterization to systematically
investigate the design principles for macrocycle membrane permeability and oral …

Recently, there has been an increasing focus on the pursuit of targets considered to be less
druggable that offer potential for development of promising new therapeutic agents for the …

Our ever‐increasing understanding of biological systems is providing a range of exciting
novel biological targets, whose modulation may enable novel therapeutic options for many …

Efficient intracellular drug delivery and target specificity are often hampered by the presence
of biological barriers. Thus, compounds that efficiently cross cell membranes are the key to …

Drug discovery for difficult targets that have large and flat binding sites is often better suited
to compounds beyond the “rule of 5”(bRo5). However, such compounds carry higher …